Try our Advanced Search for more refined results

Tollen v. Geron Corporation et al

  1. August 24, 2023

    Geron Investors' Attys Get $4.3M From $24M Stock-Drop Deal

    A California federal judge on Thursday applauded attorneys for investors in Geron Corp. as he gave final approval to a settlement with the biotechnology company and its CEO over claims they hid negative results of a clinical drug trial, saying, "This is not the greatest case ever, and you managed to get $24 million out of it."

  2. May 25, 2023

    Investor's Fiery Letter To Class Counsel Gets Criminal Referral

    A Geron Corp. investor who objected to a $24 million settlement reached with the company has been referred to criminal authorities on allegations he sent class counsel an expletive-laden demand for money that U.S. District Judge William Alsup likened to "a form of extortion." 

  3. September 06, 2022

    Geron Investors Ink $24M Deal Over Cancer Study Results

    Geron Corp. investors have reached a $24 million settlement resolving their claims that the biotechnology company and its chief executive officer hid negative results of a clinical trial for a blood cancer drug while earning millions of dollars in a stock offering, according to a recently filed motion for approval of the deal.

  4. April 13, 2021

    Alsup Trims Drug Co. Investors' Cancer Treatment Study Suit

    A federal judge in San Francisco has trimmed claims from a proposed securities class action accusing biotechnology company Geron Corp. and its chief executive officer of failing to properly explain the results of a clinical drug trial for a blood cancer drug.